Copper complexes for treatment of neurodegenerative disorders

A method of treating a neurodegenerative disease in a subject having said disease, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (V):

• or pharmaceutically acceptable salts thereof, wherein:
• R1 is C1-C6 alkyl optionally substituted with 5- to 10-memebered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
• R2 is C1-C6 alkyl optionally substituted with 5- to 10-memebered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
• R3 is 4- to 8-membered heterocycle or 5-membered heteroaryl, wherein the 4- to 8-membered heterocycle is optionally substituted one, two, or three times with the group R3a, and wherein the 5-membered heteroaryl is optionally substituted one, two, or three times with the group R3b;
• R3a independently for each occurrence is C1-C6 alkyl, C1-C6 alkyl-(C6-C10 aryl), C1-C6 alkyl-(5- to 10-membered heteroaryl), S(O)2H, S(O)2—(C1-C6 alkyl), S(O)2—(C3-C7 cycloalkyl), or S(O)2—(C6-C10 aryl);
• wherein each heteroaryl is optionally further substituted one to four times with C1-C6 alkyl or C6-C10 aryl;
• and wherein each C6-C10 aryl is optionally further substituted one to four times with C1-C6 alkyl;
• R3b independently for each occurrence is C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkyl-N(R5) 2, (C1-C6 alkyl)-O—(C1-C6 alkyl), halo, nitro, cyano, C6-C10 aryl, C(O)-(4- to 8-membered heterocycle), C1-C6 alkyl-(C6-C10 aryl), C1-C6 alkyl-(5- to 10-membered heteroaryl), or C1-C6 alkyl-(4- to 8-membered heterocycle), wherein each 4- to 8-membered heterocycle, C6-C10 aryl, and 5- to 10-membered heteroaryl are optionally further substituted one to four times with C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, or halo;
• R4 is hydrogen or C1-3 alkyl;
• and
• R5 independently for each occurrence is hydrogen, C1-C6 alkyl, or C1-C3 alkyl-(C6-C10 aryl).